Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Menorrhagia, Impaired arachidonic acid-induced platelet aggregation, Impaired collagen-induced platelet aggregation, and Increased mean platelet volume and others; and common findings: Abnormal bleeding tendency (abnormal bleeding). 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 9 | Abnormal bleeding tendency (abnormal bleeding), Impaired arachidonic acid-induced platelet aggregation, Impaired ristocetin-induced platelet aggregation |
ITGB3 encodes integrin subunit beta 3 (788 aa). Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Highest expression in Artery Aorta (59.1 TPM) and Thyroid (48.5 TPM).
Bleeding disorder, platelet-type, 24 is associated with mutations in the ITGB3 gene on chromosome 17.
ITGB3 is classified as a druggable target (Cell Surface, Druggable Genome, and External Side Of Plasma Membrane categories) with score 3.5.
Genetic testing for ITGB3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 8 always present features, 1 common feature.
No clinical trials have been registered for bleeding disorder, platelet-type, 24.
4 publications have been identified in PubMed for bleeding disorder, platelet-type, 24. Research spans Review / Meta-Analysis (50%), Clinical Trial Publication (25%), and Basic Science / Preclinical (25%).
Xiang M (2026). [PMID: 41629697](https://pubmed.ncbi.nlm.nih.gov/41629697/). *Nat Prod Bioprospect*. [Basic Science / Preclinical]
Wu J (2026). [PMID: 41503871](https://pubmed.ncbi.nlm.nih.gov/41503871/). *J Cell Mol Med*. [Review / Meta-Analysis]
Gök V (2025). [PMID: 40488176](https://pubmed.ncbi.nlm.nih.gov/40488176/). *Res Pract Thromb Haemost*. [Clinical Trial Publication]
Othman M (2025). [PMID: 40328428](https://pubmed.ncbi.nlm.nih.gov/40328428/). *J Thromb Haemost*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about bleeding disorder, platelet-type, 24